

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
300.1005CON

SERIAL NO.: 10795,411

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S): CHEN et al.

FILING DATE: March 9, 2004

GROUP: 1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA						

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
					YES	NO
AB						

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

MY	AC	Approval letter from Center for Drug Evaluation and Research to Bristol-Myers Squibb Company on NDA 21-202, Supplement 000, October 13, 2000
MY	AD	Approved Label for Glucophage/Glucophage XR, NDA 21-202, Supplement 000, October 13, 2000
MY	AE	Approval letter on labeling revision from Center for Drug Evaluation and Research to Bristol-Myers Squibb Company on NDA 21-202, Supplement 003, January 8, 2002
MY	AF	Approval letter on formulation revision from Center for Drug Evaluation and Research to Bristol-Myers Squibb Company on NDA 21-202, Supplement 008, April 11, 2003
MY	AG	Approval letter on labeling revision from Center for Drug Evaluation and Research to Bristol-Myers Squibb Company on NDA 21-202, Supplement 011, March 19, 2004
MY	AH	Approval letter on labeling revision from Center for Drug Evaluation and Research to Bristol-Myers Squibb Company on NDA 21-202, Supplement 013, March 19, 2004
MY	AI	Approval letter on labeling revision from Center for Drug Evaluation and Research to Bristol-Myers Squibb Company on NDA 21-202, Supplement 001, April 19, 2001
MY	AJ	Approved Label For Glucophage/Glucophage XR NDA 21-202, Supplement 013, March 19, 2004
MY	AK	Approved Label for Glucophage/Glucophage XR NDA 21-202, Supplement 011, March 19, 2004
MY	AL	Approved Label for Glucophage/Glucophage XR NDA 21-201, Supplement 008, labeling revision, April 11, 2003
	AM	
	AN	
	AO	
	AP	
	AQ	
	AR	
	AS	

EXAMINER /Micah Paul Young/

DATE CONSIDERED 07/12/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				ATTY. DOCKET NO.: 300.1005CON		SERIAL NO.: 10/796,411						
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)						APPLICANT(S): CHEN et al.								
						FILING DATE: March 9, 2004		GROUP: 1615						
U.S. PATENT DOCUMENTS														
*EXAMINER INITIAL	BA	DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
MY	BA	5	9	1	4	3	2	6	06/22/99	McCarty et al.	514	188		
MY	BB	6	1	1	7	4	5	1	09/12/00	Kumar	424	465		
MY	BC	5	1	0	0	6	6	9	03/31/92	Hyon, et al.	424	426		
MY	BD	5	8	3	7	3	7	9	11/17/98	Chen et al.	424	465		
MY	BE	6	0	5	6	9	7	7	05/02/00	Bhagwat et al.	424	488		
MY	BF	20	06	00	34	9	2	2	02/16/06	Cheng et al.				
MY	BG	20	06	00	08	5	2	5	01/12/06	Chen et al.				
MY	BH	20	06	00	08	5	2	4	01/12/06	Chen et al.				
MY	BI	20	06	00	08	5	2	3	01/12/06	Chen et al.				
MY	BJ	20	06	00	08	5	2	6	01/12/06	Chen et al.				
MY	BK	20	04	00	52	8	4	8	03/18/04	Cheng et al.				
MY	BL	20	01	00	24	6	5	9	09/27/01	Chen et al.				
FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
MY	BM	2	2	5	1	4	3	0	02/28/00	CA	A61K	31/44		
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)														
MY	BN	E.K. Kastrop: "Anidiabetic Agents," DRUG FACTS AND COMPARISONS, 1999, St. Louis, pp 635-642												
MY	BO	Physicians' Desk Reference, "Glucophage XR," 56 th edition, pages 1080-1086												
MY	BP	Physicians' Desk Reference, "Glucophage," 52 nd edition, pages 795-800												
MY	BQ	STN Registry Search for Metformin												
	BR													
	BS													
EXAMINER /Micah Paul Young/										DATE CONSIDERED 07/12/2006				
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>														